Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 23;192(2):103.
doi: 10.1007/s00604-024-06822-2.

Nanoenzyme-based sensors for the detection of anti-tumor drugs

Affiliations
Review

Nanoenzyme-based sensors for the detection of anti-tumor drugs

Xiaojing Zhang et al. Mikrochim Acta. .

Abstract

Natural enzymes are a class of biological catalysts that can catalyze a specific substrate. Although natural enzymes have catalytic activity, they are susceptible to the influence of external environment such as temperature, and storage requirements are more stringent. Since the first discovery of magnetic Fe3O4 nanoparticles with peroxidase-like activity in 2007, the research on nanoenzymes has entered a rapid development stage. Nanoenzymes synthesized by chemical methods not only have the catalytic activity of natural enzymes but also are more stable, easy to store, and convenient to prepare. Anthracyclines, as a commonly used anti-tumor chemotherapy drug, will produce many side effects such as myelosuppression and liver function damage after long-term use, which will affect its therapeutic effects. This paper reviews the characteristics, classification, and mechanisms of nanoenzymes. The detection of anti-tumor drugs, especially anthracycline drugs, using a nanoenzyme-based sensor was emphatically introduced. On this basis, the application of nanoenzyme-based sensors in the detection of anti-tumor drugs is prospected.

Keywords: Anthracyclines; Anti-tumor drugs; Colorimetric sensor; Electrochemical sensors; Fluorescent sensors; Nanoenzymes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Humans and animal rights and informed consent: This research did not involve human or animal samples. Conflict of interest: The authors declare no competing interests.

Similar articles

Cited by

References

    1. Ibrahim A, El Baldi M, Mohammed S et al (2024) Cancer statistics in Yemen: incidence and mortality, in 2020. BMC Public Health 24(1):962. https://doi.org/10.1186/s12889-024-18207-4 - DOI - PubMed - PMC
    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–49. https://doi.org/10.3322/caac.21660 - DOI - PubMed
    1. Coles CE, Earl H, Anderson BO et al (2024) The Lancet Breast Cancer Commission. Lancet. https://doi.org/10.1016/s0140-6736(24)00747-5
    1. James ND, Tannock I, N’Dow J et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403(10437):1683–722. https://doi.org/10.1016/s0140-6736(24)00651-2 - DOI - PubMed - PMC
    1. Samara P, Athanasopoulos M, Goulioumis A et al (2023) Malignant tumors of the external auditory canal: diagnosis, treatment, genetic landscape, biomarkers, and clinical outcome. Explor Target Antitumor Ther 4(5): 801–11. https://doi.org/10.37349/etat.2023.00169

MeSH terms